Active
A Non-Randomized, Open-Label, Phase 2 Study of Trametinib in Patients With Unresectable or Metastatic Epithelioid Hemangioendothelioma
Type of Sarcoma:
Epithelioid Hemangioendothelioma
Drug:
Trametinib
Accrual Status:
Not Recruiting
Overall Study Principal Investigator:
Scott Schuetze, MD, PhD
Division of Hematology/Oncology
University of Michigan Comprehensive Cancer Center EDDOP
Division of Hematology/Oncology
University of Michigan Comprehensive Cancer Center EDDOP